XBI240726P94000
- 0.14
- -0.21-60.00%
SPDR S&P Biotech ETF Newsroom
$100 Invested In This Stock 15 Years Ago Would Be Worth $5,100 Today
Regeneron Pharmaceuticals (NASDAQ:REGN) has outperformed the market over the past 15 years by 17.42% on an annualized basis producing an average annual return of 29.68%. Currently, Regeneron
AnaptysBio Investigational Arthritis Drug Might Have Better Efficacy Profile Than Eli Lilly's: Analyst
HC Wainwright analyst initiated coverage on AnaptysBio Inc (NASDAQ:ANAB), a clinical-stage biotechnology company focused on delivering immunology therapeutics.AnaptysBio has a pipeline of checkpoint
Ionis' Rare Development Disorder Drug Candidate 'Could Be Differentiated' From Peer Ultragenyx: Analyst
Ionis Pharmaceuticals Inc (NASDAQ:IONS) released results Monday from the completed multiple ascending dose (MAD) portion of the Phase 1/2 open-label study of ION582 in people with Angelman syndrome (
A Glimpse Into The Expert Outlook On Biomarin Pharmaceutical Through 10 Analysts
Ratings for Biomarin Pharmaceutical (NASDAQ:BMRN) were provided by 10 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.The following table encapsulates their
Breaking Down Gilead Sciences: 10 Analysts Share Their Views
Gilead Sciences (NASDAQ:GILD) underwent analysis by 10 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.The table below offers a condensed view of their
Regeneron Pharmaceuticals Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 07/22/2024 -7.62% Cantor Fitzgerald $925 → $1000 Maintains Neutral 07/19/2024 7.72% Piper Sandler $1000 →
Gilead Sciences Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 07/22/2024 -3.49% Cantor Fitzgerald $75 → $70 Maintains Neutral 07/08/2024 28.22% Raymond James → $93
Biomarin Pharmaceutical Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 07/22/2024 28.93% Cantor Fitzgerald $110 → $110 Reiterates Overweight → Overweight 06/27/2024 34.79%
Alnylam Pharmaceuticals Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 07/22/2024 -6.83% Cantor Fitzgerald $150 → $220 Maintains Neutral 07/12/2024 8% Morgan Stanley $250 → $255
Kamala Harris' Potential Impact on Health Care Stocks
With President Joe Biden earlier Sunday saying he will end his campaign for re-election and endorsing Vice President Kamala Harris, the focus now turns on her positions on issues.
Here Are Big Pharma's Leading Blockbuster Makers
What to Expect in the Week Ahead (Google and Tesla Earnings; GDP and PCE Data)
This week, investors should keep an eye on earnings reports from several key players, including Google and Tesla. Key economic data to watch for will include the release of the first estimate of second-quarter gross domestic product and the Federal Reserve's preferred inflation measure for June.
Financials Dominate in Q2 as Wall Street Slides Amidst Concerns on Tech - Earnings Scorecard
Catalyst Watch: Earnings Deluge, Farnborough Airshow, Paris Olympics, and Trump Talks Crypto
Check Out What Whales Are Doing With GILD
Whales with a lot of money to spend have taken a noticeably bullish stance on Gilead Sciences.Looking at options history for Gilead Sciences (NASDAQ:GILD) we detected 9 trades.If we consider the
Peeling Back The Layers: Exploring AbbVie Through Analyst Insights
Analysts' ratings for AbbVie (NYSE:ABBV) over the last quarter vary from bullish to bearish, as provided by 10 analysts.The following table provides a quick overview of their recent ratings,
Peering Into Regeneron Pharmaceuticals's Recent Short Interest
Regeneron Pharmaceuticals's (NYSE:REGN) short percent of float has risen 10.17% since its last report. The company recently reported that it has 2.04 million shares sold short, which is 1.95% of all
AbbVie Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 07/19/2024 24.78% BMO Capital $180 → $214 Maintains Outperform 07/11/2024 14.29% Morgan Stanley $191 → $19
Vertex Pharmaceuticals Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 07/19/2024 2.43% HC Wainwright & Co. $462 → $500 Maintains Buy 07/11/2024 -6.79% Morgan Stanley $402 → $45
EXCLUSIVE: Weight-Loss Duopoly Breaks As Eli Lilly, Novo Plummet; 'Market Won't Be Dominated By Just 2 Players'
GLP-1 market leaders Eli Lilly and Company (NYSE:LLY) and Novo Nordisk A/S (NYSE:NVO) faced a significant selloff on Thursday, as new weight-loss drugs from rival pharmaceutical companies began threatening the dominance of their flagship products, Zepbound and Wegovy.